Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INSYS Therapeutics, Inc.
NEW YORK, Dec. 13, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of INSYS Therapeutics, Inc. ("INSYS" or the "Company") (NasdaqGM: INSY). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at [email protected] or 212-697-6484.
The investigation concerns whether INSYS and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 13, 2013, shares of INSYS fell $10.01 or 22.19% during intraday trading to trade at $35.10 after the Company disclosed after market closed on December 12, 2013 that the Company has received a subpoena from the Office of Inspector General of the Department of Health and Human Services (HHS), in connection with an investigation of potential violations involving HHS programs. According to a Company-issued press release, "the subpoena requests documents regarding Subsys®, including Insys' sales and marketing practices relating to this product."
If you are aware of any facts relating to this investigation, or purchased shares of INSYS you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article